BIOMAT Database Logo BIOMAT Database Logo

A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. 1994

A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

To evaluate the effect of adding amikacin (AMK) to imipenem-cilastatin (IPM/CS), we conducted a randomized controlled trial in patients who experienced neutropenia (< 1,000/mm3) and fever (> 38 degrees C) induced by cancer chemotherapy. There were 70 patients who entered the trial; 34 and 36 patients received IPM/CS plus AMK (arm A) and IPM/CS (arm B), respectively. There was no significant difference in patient characteristics between the two groups. Among 67 evaluable patients, 29 of 32 (91%) and 25 of 35 (71%) responded to the antibiotics therapy in arm A and B, respectively, with EORTC criteria (p < .047). Median days of antibiotics administration and of febrile episode over 38 degrees C were not statistically significantly different between arm A and B. There was no patient with severe side effects, such as seizure, and 17 patients (30%) experienced emesis in both groups. These data suggest IPM/CS plus AMK is therapeutically superior to IPM/CS alone in patients with neutropenic fever induced by cancer chemotherapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
[Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
March 1995, Revista medica de Chile,
A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
January 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
May 2005, Current medical research and opinion,
A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
Imipenem/cilastatin as initial therapy for febrile neutropenic patients.
November 1988, The Journal of antimicrobial chemotherapy,
A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
Imipenem/cilastatin monotherapy as salvage treatment in febrile neutropenic patients.
October 1996, Journal of chemotherapy (Florence, Italy),
A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
January 1996, Infection,
A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders.
April 1992, Journal of chemotherapy (Florence, Italy),
A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
February 1992, Archives of internal medicine,
A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
January 1987, Scandinavian journal of infectious diseases. Supplementum,
A Kojima, and T Shinkai, and Y Soejima, and H Okamoto, and K Eguchi, and Y Sasaki, and T Tamura, and F Oshita, and Y Ohe, and N Saijo
Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.
July 1999, The Korean journal of internal medicine,
Copied contents to your clipboard!